Clearbridge Investments LLC Reduces Stock Holdings in AbbVie Inc. $ABBV

Clearbridge Investments LLC decreased its stake in AbbVie Inc. (NYSE:ABBV) by 18.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 890,125 shares of the company’s stock after selling 204,014 shares during the period. Clearbridge Investments LLC’s holdings in AbbVie were worth $203,385,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Syon Capital LLC lifted its stake in shares of AbbVie by 4.3% during the 4th quarter. Syon Capital LLC now owns 25,917 shares of the company’s stock worth $5,922,000 after acquiring an additional 1,078 shares during the last quarter. Capital World Investors lifted its stake in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after acquiring an additional 6,736,161 shares during the last quarter. Capital Research Global Investors lifted its stake in shares of AbbVie by 0.7% during the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after acquiring an additional 177,370 shares during the last quarter. Capital International Sarl lifted its stake in shares of AbbVie by 62.4% during the 4th quarter. Capital International Sarl now owns 65,836 shares of the company’s stock worth $15,043,000 after acquiring an additional 25,294 shares during the last quarter. Finally, Capital International Ltd. CA lifted its stake in shares of AbbVie by 33.4% during the 4th quarter. Capital International Ltd. CA now owns 25,292 shares of the company’s stock worth $5,779,000 after acquiring an additional 6,332 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Morgan Stanley raised their price target on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $240.00 price target on shares of AbbVie in a research note on Thursday, April 30th. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target for the company. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Stock Up 0.2%

Shares of NYSE ABBV opened at $227.68 on Monday. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The business has a fifty day simple moving average of $209.85 and a two-hundred day simple moving average of $219.26. The firm has a market cap of $402.27 billion, a PE ratio of 112.16, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the business posted $2.46 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. On average, research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.